Literature DB >> 6502081

Patients' willingness to take risks in the management of pharyngitis.

J M Herman.   

Abstract

Choosing a management plan for pharyngitis involves considering the risks and benefits of alternatives. Using a sick-day equivalent scale, this study examined patients' willingness to be ill with pharyngitis compared with their willingness to risk two outcomes: a penicillin reaction and rheumatic fever. On average, patients preferred 1.5 to 2.5 days of illness with pharyngitis over risking a 5-percent chance of developing a mild penicillin reaction. Willingness to risk the outcomes decreased with increasing probabilities of their occurrence. Subjects were more willing to risk a penicillin reaction than rheumatic fever. Healthy subjects receiving sick pay were more willing to risk varying probabilities of a mild penicillin reaction than subjects not receiving sick pay. Patients ill with pharyngitis, however, were not more willing to take similar risks if they received sick pay. Illness may, therefore, modify some aspects of risk-taking behavior. It is reasonable to conclude that some patients with pharyngitis would prefer early antibiotic treatment for the chance of earlier recovery over waiting for throat culture results despite the risk of a penicillin reaction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502081

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  3 in total

Review 1.  Antibiotics for acute bronchitis.

Authors:  Susan M Smith; Tom Fahey; John Smucny; Lorne A Becker
Journal:  Cochrane Database Syst Rev       Date:  2017-06-19

2.  The effect of erythromycin on resolution of symptoms among adults with pharyngitis not caused by group A streptococcus.

Authors:  K Petersen; R S Phillips; J Soukup; A L Komaroff; M Aronson
Journal:  J Gen Intern Med       Date:  1997-02       Impact factor: 5.128

3.  What a difference a day makes: a decision analysis of adult streptococcal pharyngitis.

Authors:  B E Hillner; R M Centor
Journal:  J Gen Intern Med       Date:  1987 Jul-Aug       Impact factor: 5.128

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.